Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced the pricing of an underwritten public offering of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Equity Offerings

Veru, Inc. (VERU) Reports First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation TherapyOctober 1, 2018 7:31 AM Veru Announces Pricing of Public Offering of Common StockSeptember 27, 2018 9:05 AM Veru, Inc. (VERU) Announces Proposed Common Share OfferingSeptember 26, 2018 4:02 PM Veru Announces Proposed Public Offering of Common StockSeptember 26, 2018 4:01 PM